The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Denosumab (Prolia®) has been rejected for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« Ciclesonide supply interruption||NICE Guidance - September 2018 »|